B. Riley Wealth Advisors Inc. Has $26.11 Million Holdings in Eli Lilly and Company (NYSE:LLY)

B. Riley Wealth Advisors Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,816 shares of the company's stock after selling 3,491 shares during the quarter. Eli Lilly and Company accounts for about 0.9% of B. Riley Wealth Advisors Inc.'s portfolio, making the stock its 13th largest holding. B. Riley Wealth Advisors Inc.'s holdings in Eli Lilly and Company were worth $26,106,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $8,407,908,000. Proficio Capital Partners LLC grew its holdings in Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares in the last quarter. Wellington Management Group LLP grew its holdings in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter. Capital International Investors grew its holdings in Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after buying an additional 1,645,222 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $1,240,653,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.0%

Eli Lilly and Company stock traded up $0.15 during trading hours on Thursday, hitting $719.54. The company had a trading volume of 1,209,647 shares, compared to its average volume of 3,615,619. The firm has a market capitalization of $681.93 billion, a P/E ratio of 61.44, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm's fifty day moving average is $782.03 and its 200-day moving average is $801.29. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the company posted $2.58 earnings per share. The company's revenue was up 45.2% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. Eli Lilly and Company's payout ratio is presently 48.82%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.